Arch Biopartners Inc. (ARCH.V)

CAD 1.7

(-2.86%)

Market Cap (In CAD)

110.25 Million

Revenue (In CAD)

1.98 Million

Net Income (In CAD)

-3.32 Million

Avg. Volume

13.79 Thousand

Currency
CAD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
1.31-2.56
PE
-
EPS
-
Beta Value
1.39
ISIN
CA03938C1041
CUSIP
-
CIK
-
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Mr. Richard Gabriel Muruve
Employee Count
-
Website
https://www.archbiopartners.com
Ipo Date
2010-05-07
Details
Arch Biopartners Inc., a biotechnology company, develops technologies for medical or commercial impact. It focuses on developing its lead drug candidate Metablok to treat or prevent dipeptidase-1 mediated organ inflammation in the lungs, liver, or kidneys, which results in organ damage or failure, including in the case of sepsis and COVID-19. The company also develops AB569, a drug candidate for treating or preventing antibiotic resistant bacterial infections, primarily as a topical treatment for wounds. In addition, it develops Borg, a peptide-solid surface interface to inhibit biofilm formation and reduce corrosion; and MetaMx, which are synthetic molecules that target brain tumor initiating cells and invasive glioma cells. The company is based in Toronto, Canada.